magnolol has been researched along with Diabetes Mellitus, Type 1 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X; Ouyang, X; Qian, M; Shen, X; Wang, J; Wei, Y; Yang, J; Zhan, X; Zhao, T; Zhao, X; Zhou, L | 1 |
1 other study(ies) available for magnolol and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Magnolol effectively ameliorates diabetic peripheral neuropathy in mice.
Topics: AMP-Activated Protein Kinases; Animals; Biological Products; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Hypoglycemic Agents; Lignans; Male; Mice; NF-kappa B; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Sciatic Nerve; Sirtuin 1 | 2022 |